Strontium  ||| S:0 E:10 ||| FW
ranelate  ||| S:10 E:19 ||| FW
in  ||| S:19 E:22 ||| FW
post-menopausal  ||| S:22 E:38 ||| FW
osteoporosis  ||| S:38 E:51 ||| FW
Strontium  ||| S:51 E:61 ||| FW
ranelate  ||| S:61 E:70 ||| FW
is  ||| S:70 E:73 ||| VBZ
one  ||| S:73 E:77 ||| CD
of  ||| S:77 E:80 ||| IN
the  ||| S:80 E:84 ||| DT
first-line  ||| S:84 E:95 ||| JJ
agents  ||| S:95 E:102 ||| NNS
with  ||| S:102 E:107 ||| IN
proven  ||| S:107 E:114 ||| JJ
anti-fracture  ||| S:114 E:128 ||| JJ
activity  ||| S:128 E:137 ||| NN
used  ||| S:137 E:142 ||| VBN
in  ||| S:142 E:145 ||| IN
the  ||| S:145 E:149 ||| DT
therapy  ||| S:149 E:157 ||| NN
of  ||| S:157 E:160 ||| IN
post-menopausal  ||| S:160 E:176 ||| JJ
osteoporosis ||| S:176 E:188 ||| NN
.  ||| S:188 E:190 ||| .
Its  ||| S:190 E:194 ||| PRP$
mechanism  ||| S:194 E:204 ||| NN
of  ||| S:204 E:207 ||| IN
action  ||| S:207 E:214 ||| NN
makes  ||| S:214 E:220 ||| VBZ
it ||| S:220 E:222 ||| PRP
,  ||| S:222 E:224 ||| ,
however ||| S:224 E:231 ||| RB
,  ||| S:231 E:233 ||| ,
different  ||| S:233 E:243 ||| JJ
from  ||| S:243 E:248 ||| IN
other  ||| S:248 E:254 ||| JJ
drugs ||| S:254 E:259 ||| NNS
,  ||| S:259 E:261 ||| ,
since  ||| S:261 E:267 ||| IN
it  ||| S:267 E:270 ||| PRP
simultaneously  ||| S:270 E:285 ||| RB
stimulates  ||| S:285 E:296 ||| CD
two  ||| S:296 E:300 ||| CD
reverse  ||| S:300 E:308 ||| JJ
processes ||| S:308 E:317 ||| NNS
:  ||| S:317 E:319 ||| :
bone  ||| S:319 E:324 ||| JJ
formation  ||| S:324 E:334 ||| NN
and  ||| S:334 E:338 ||| CC
bone  ||| S:338 E:343 ||| NN
resorption ||| S:343 E:353 ||| NN
.  ||| S:353 E:355 ||| .
The  ||| S:355 E:359 ||| DT
action  ||| S:359 E:366 ||| NN
of  ||| S:366 E:369 ||| IN
the  ||| S:369 E:373 ||| DT
agent  ||| S:373 E:379 ||| NN
depends  ||| S:379 E:387 ||| VBZ
on  ||| S:387 E:390 ||| IN
various  ||| S:390 E:398 ||| JJ
mechanisms ||| S:398 E:408 ||| NNS
,  ||| S:408 E:410 ||| ,
including  ||| S:410 E:420 ||| VBG
the  ||| S:420 E:424 ||| DT
activation  ||| S:424 E:435 ||| NN
of  ||| S:435 E:438 ||| IN
calcium  ||| S:438 E:446 ||| JJ
receptors ||| S:446 E:455 ||| NNS
,  ||| S:455 E:457 ||| ,
localised  ||| S:457 E:467 ||| VBG
on  ||| S:467 E:470 ||| IN
osteoblasts  ||| S:470 E:482 ||| NN
and  ||| S:482 E:486 ||| CC
osteoclasts ||| S:486 E:497 ||| NN
,  ||| S:497 E:499 ||| ,
and  ||| S:499 E:503 ||| CC
on  ||| S:503 E:506 ||| IN
the  ||| S:506 E:510 ||| DT
influence  ||| S:510 E:520 ||| NN
on  ||| S:520 E:523 ||| IN
the  ||| S:523 E:527 ||| DT
OPG ||| S:527 E:530 ||| NNP
/ ||| S:530 E:531 ||| NNP
RANKL  ||| S:531 E:537 ||| NNP
system ||| S:537 E:543 ||| NN
.  ||| S:543 E:545 ||| .
The  ||| S:545 E:549 ||| DT
drug  ||| S:549 E:554 ||| NN
effectively  ||| S:554 E:566 ||| RB
prevents  ||| S:566 E:575 ||| VBZ
spinal ||| S:575 E:581 ||| JJ
,  ||| S:581 E:583 ||| ,
hip  ||| S:583 E:587 ||| NN
and  ||| S:587 E:591 ||| CC
extravertebral  ||| S:591 E:606 ||| JJ
fractures ||| S:606 E:615 ||| NN
.  ||| S:615 E:617 ||| .
The  ||| S:617 E:621 ||| DT
agent ||| S:621 E:626 ||| NN
's  ||| S:626 E:629 ||| POS
anti-fracture  ||| S:629 E:643 ||| JJ
efficacy  ||| S:643 E:652 ||| NN
within  ||| S:652 E:659 ||| IN
the  ||| S:659 E:663 ||| DT
spine  ||| S:663 E:669 ||| NN
does  ||| S:669 E:674 ||| VBZ
not  ||| S:674 E:678 ||| RB
depend  ||| S:678 E:685 ||| VB
on  ||| S:685 E:688 ||| IN
the  ||| S:688 E:692 ||| DT
patient ||| S:692 E:699 ||| NN
's  ||| S:699 E:702 ||| POS
age ||| S:702 E:705 ||| NN
,  ||| S:705 E:707 ||| ,
or  ||| S:707 E:710 ||| CC
on  ||| S:710 E:713 ||| IN
base  ||| S:713 E:718 ||| NN
BMD  ||| S:718 E:722 ||| NN
values ||| S:722 E:728 ||| NNS
,  ||| S:728 E:730 ||| ,
or  ||| S:730 E:733 ||| CC
on  ||| S:733 E:736 ||| IN
the  ||| S:736 E:740 ||| DT
concentration  ||| S:740 E:754 ||| NN
of  ||| S:754 E:757 ||| IN
bone  ||| S:757 E:762 ||| NN
metabolism  ||| S:762 E:773 ||| NN
markers ||| S:773 E:780 ||| NN
.  ||| S:780 E:782 ||| .
As  ||| S:782 E:785 ||| RB
to  ||| S:785 E:788 ||| TO
the  ||| S:788 E:792 ||| DT
anti-fracture  ||| S:792 E:806 ||| JJ
efficacy  ||| S:806 E:815 ||| NN
in  ||| S:815 E:818 ||| IN
the  ||| S:818 E:822 ||| DT
hip ||| S:822 E:825 ||| NN
,  ||| S:825 E:827 ||| ,
it  ||| S:827 E:830 ||| PRP
concerns  ||| S:830 E:839 ||| VBZ
women  ||| S:839 E:845 ||| NNS
with  ||| S:845 E:850 ||| IN
an  ||| S:850 E:853 ||| DT
increased  ||| S:853 E:863 ||| JJ
bone  ||| S:863 E:868 ||| NN
fracture  ||| S:868 E:877 ||| NN
risk ||| S:877 E:881 ||| NN
.  ||| S:881 E:883 ||| .
Strontium  ||| S:883 E:893 ||| JJ
ranelate  ||| S:893 E:902 ||| JJ
increases  ||| S:902 E:912 ||| NNS
bone  ||| S:912 E:917 ||| NN
mineral  ||| S:917 E:925 ||| NN
density  ||| S:925 E:933 ||| NN
within  ||| S:933 E:940 ||| IN
the  ||| S:940 E:944 ||| DT
lumbar  ||| S:944 E:951 ||| JJ
spine  ||| S:951 E:957 ||| NN
and  ||| S:957 E:961 ||| CC
the  ||| S:961 E:965 ||| DT
hip ||| S:965 E:968 ||| NN
,  ||| S:968 E:970 ||| ,
decreases  ||| S:970 E:980 ||| VBZ
the  ||| S:980 E:984 ||| DT
concentrations  ||| S:984 E:999 ||| NNS
of  ||| S:999 E:1002 ||| IN
bone  ||| S:1002 E:1007 ||| JJ
resorption  ||| S:1007 E:1018 ||| JJ
markers ||| S:1018 E:1025 ||| NN
,  ||| S:1025 E:1027 ||| ,
and  ||| S:1027 E:1031 ||| CC
increases  ||| S:1031 E:1041 ||| VBZ
the  ||| S:1041 E:1045 ||| DT
concentrations  ||| S:1045 E:1060 ||| NNS
of  ||| S:1060 E:1063 ||| IN
bone  ||| S:1063 E:1068 ||| NN
formation  ||| S:1068 E:1078 ||| NN
markers ||| S:1078 E:1085 ||| NN
.  ||| S:1085 E:1087 ||| .
The  ||| S:1087 E:1091 ||| DT
drug  ||| S:1091 E:1096 ||| NN
is  ||| S:1096 E:1099 ||| VBZ
administered  ||| S:1099 E:1112 ||| VBN
in  ||| S:1112 E:1115 ||| IN
a  ||| S:1115 E:1117 ||| DT
daily  ||| S:1117 E:1123 ||| JJ
2.0  ||| S:1123 E:1127 ||| CD
g  ||| S:1127 E:1129 ||| CD
oral  ||| S:1129 E:1134 ||| JJ
dose ||| S:1134 E:1138 ||| NN
.  ||| S:1138 E:1140 ||| .
This  ||| S:1140 E:1145 ||| DT
paper  ||| S:1145 E:1151 ||| NN
presents  ||| S:1151 E:1160 ||| VBZ
indications  ||| S:1160 E:1172 ||| NNS
to  ||| S:1172 E:1175 ||| TO
therapy  ||| S:1175 E:1183 ||| NN
with  ||| S:1183 E:1188 ||| IN
strontium  ||| S:1188 E:1198 ||| JJ
ranelate ||| S:1198 E:1206 ||| NN
,  ||| S:1206 E:1208 ||| ,
specifying  ||| S:1208 E:1219 ||| VBG
also  ||| S:1219 E:1224 ||| RB
its  ||| S:1224 E:1228 ||| PRP$
side  ||| S:1228 E:1233 ||| NN
effects  ||| S:1233 E:1241 ||| NNS
and  ||| S:1241 E:1245 ||| CC
contraindications ||| S:1245 E:1262 ||| NN
.  ||| S:1262 E:1264 ||| .
We  ||| S:1264 E:1267 ||| PRP
compare  ||| S:1267 E:1275 ||| VBP
the  ||| S:1275 E:1279 ||| DT
anti-fracture  ||| S:1279 E:1293 ||| JJ
efficacy  ||| S:1293 E:1302 ||| NN
of  ||| S:1302 E:1305 ||| IN
strontium  ||| S:1305 E:1315 ||| JJ
ranelate  ||| S:1315 E:1324 ||| NN
to  ||| S:1324 E:1327 ||| TO
the  ||| S:1327 E:1331 ||| DT
efficacy  ||| S:1331 E:1340 ||| NN
of  ||| S:1340 E:1343 ||| IN
other  ||| S:1343 E:1349 ||| JJ
agents  ||| S:1349 E:1356 ||| NNS
of  ||| S:1356 E:1359 ||| IN
proven  ||| S:1359 E:1366 ||| JJ
anti-fracture  ||| S:1366 E:1380 ||| JJ
activity ||| S:1380 E:1388 ||| NN
,  ||| S:1388 E:1390 ||| ,
based  ||| S:1390 E:1396 ||| VBN
on  ||| S:1396 E:1399 ||| IN
published  ||| S:1399 E:1409 ||| VBN
clinical  ||| S:1409 E:1418 ||| JJ
studies ||| S:1418 E:1425 ||| NNS
.  ||| S:1425 E:1427 ||| .
